ADMA Biologics (ADMA) to Release Earnings on Thursday

ADMA Biologics (NASDAQ:ADMA - Get Free Report) is set to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect ADMA Biologics to post earnings of $0.05 per share for the quarter. ADMA Biologics has set its FY 2024 guidance at EPS and its FY 2025 guidance at EPS.Individual that wish to register for the company's earnings conference call can do so using this link.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. The company had revenue of $73.90 million for the quarter, compared to the consensus estimate of $73.50 million. On average, analysts expect ADMA Biologics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Trading Up 1.0 %

Shares of ADMA traded up $0.07 during mid-day trading on Friday, hitting $6.81. 2,985,565 shares of the company's stock traded hands, compared to its average volume of 2,595,932. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04. The firm has a market capitalization of $1.55 billion, a P/E ratio of -52.38 and a beta of 0.43. The business's 50-day moving average price is $6.21 and its 200-day moving average price is $4.99. ADMA Biologics has a 1 year low of $3.06 and a 1 year high of $6.81.

Insiders Place Their Bets

In other ADMA Biologics news, Director Steve Elms sold 183,008 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $6.01, for a total value of $1,099,878.08. Following the completion of the transaction, the director now owns 2,577,387 shares in the company, valued at $15,490,095.87. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 639,895 shares of company stock worth $3,927,169. 6.00% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Mizuho upped their target price on ADMA Biologics from $9.00 to $10.00 and gave the company a "buy" rating in a report on Friday, March 1st. Cantor Fitzgerald upped their target price on ADMA Biologics from $6.50 to $8.00 and gave the company an "overweight" rating in a report on Thursday, February 29th. Finally, HC Wainwright restated a "buy" rating and set a $7.50 target price (up previously from $6.00) on shares of ADMA Biologics in a report on Tuesday, March 26th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $7.88.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.